Tandem Diabetes Care Inc
TNDM: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$21.00 | Qprw | Qzpxskq |
Tandem Diabetes Poised for Return to Growth Thanks to Mobi
Business Strategy and Outlook
Though Tandem Diabetes has made a splash in the insulin pump market as the latest entrant in the US, the firm is still endeavoring to establish itself as a major competitor. On this rather lengthy path between the initial 2012 launch of its original t:slim pump and consistent positive earnings, Tandem still has a few years to go, from our perspective.